Clover Health/$CLOV
1D1W1MYTD1Y5YMAX
Capital at risk
About Clover Health
Clover Health Investments Corp is a healthcare technology company. It focuses on empowering Medicare physicians to proactively manage chronic diseases through its proprietary software platform, Clover Assistant. This cloud-based solution provides personalized insights to physicians, enabling early detection and management of chronic conditions. It operates in one segment: Insurance, through which it offers PPO and HMO plans to Medicare Advantage members in several states.
- Ticker
- $CLOV
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 724
- Headquarters
- Wilmington, United States
- Website
- www.cloverhealth.com
Clover Health Metrics
BasicAdvanced
$2.4B
-
-$0.04
2.48
-
Price and volume
Market cap
$2.4B
Beta
2.48
52-week high
$5.59
52-week low
$1.58
Average daily volume
4.4M
Financial strength
Current ratio
1.501
Quick ratio
1.379
Profitability
EBITDA (TTM)
-17.956
Gross margin (TTM)
18.54%
Net profit margin (TTM)
-0.74%
Operating margin (TTM)
-0.74%
Revenue per employee (TTM)
$3,420,000
Management effectiveness
Return on assets (TTM)
-1.77%
Return on equity (TTM)
-5.10%
Valuation
Price to revenue (TTM)
0.957
Price to book
6.41
Price to tangible book (TTM)
6.46
Price to free cash flow (TTM)
31.919
Free cash flow yield (TTM)
3.13%
Free cash flow per share (TTM)
0.143
Growth
Revenue change (TTM)
53.98%
Earnings per share change (TTM)
-52.27%
3-year revenue growth (CAGR)
0.47%
3-year earnings per share growth (CAGR)
-57.86%
What the Analysts think about Clover Health
Analyst ratings (Buy, Hold, Sell) for Clover Health stock.
Analyst projections of the future price of Clover Health stock.
Bulls say / Bears say
Clover’s Q2 2026 results showed strong operating momentum: Medicare Advantage membership rose 48% year over year to 157,309, revenue increased 56% to $743 million, adjusted EBITDA rose 139% to $40.9 million, and GAAP net income reached $28 million. (SEC)
Management raised full-year 2026 guidance to $2.92-$3.00 billion of revenue, $70-$85 million of adjusted EBITDA, and $20-$35 million of GAAP net income, suggesting improving scale economics and a credible path to sustained profitability. (SEC)
CMS’s recalculation raised both Clover’s PPO and HMO contracts to 4.5 stars for the 2027 payment year, improving the company’s quality-bonus-payment position and giving it more flexibility on benefits, growth, and margins. (SEC)
Clover remains highly exposed to medical-cost execution because it retains full underwriting risk: Q2 2026 insurance claims were $615.4 million against $737.8 million of insurance revenue, producing an 87.6% benefits-expense ratio. (SEC)
Clover’s cost structure and diversification remain works in progress: management acknowledges its operating-expense ratio is higher than peers because it invested ahead of scale, while Counterpart Health is still focused on adoption and demonstrating value rather than making a meaningful near-term financial contribution. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 10 Sept 2026.
Clover Health Financial Performance
Revenues and expenses
Clover Health Earnings Performance
Company profitability
Upcoming events
No upcoming events
Clover Health News
AllArticlesVideos
Funds containing Clover Health
AllEURUSDGBP
Fund name | Fund size | $CLOV weighting |
|---|---|---|
iShares Ageing Population€AGED | €822M | 0.17% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.07% |
iShares MSCI World Small Cap$WSML | $9B | 0.02% |
iShares MSCI World Small Cap€IUSN | €7.8B | 0.02% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.